Heron Therapeutics Posts Strong Q1 Growth as CMS Policy and Mylan Settlement Shape Outlook

Heron Therapeutics Inc. (HRTX)

Ticker	Exchange	Price (USD)	% Change (24h)	Volume
HRTX	NASDAQ	1.3145	–28.56%	6,107,022

Heron Therapeutics Inc. is a commercial-stage biotechnology company founded in 1983 and headquartered in Cary, North Carolina. The company utilizes its proprietary Biochronomer™ drug-delivery platform to improve the therapeutic profile of injectable pharmaceuticals. Heron’s approved products are designed to address chemotherapy-induced nausea and vomiting (CINV) and postoperative pain and nausea.

Corporate Structure

Heron employs between 51 and 200 staff members across its research, development, commercial, and corporate functions. The company’s key facilities include its Cary, NC headquarters and offices in San Diego, CA. Heron’s leadership team consists of executives with backgrounds in pharmaceutical R&D, regulatory affairs, and commercial operations, who support a product portfolio in acute care and oncology.

Biotechnology by Sangharsh Lohakare

Recent Developments and News

• On May 6, 2025, Heron reported first-quarter 2025 net revenue of $38.9 million and adjusted EBITDA of $6.2 million. Net revenue grew 12.2% compared to Q1 2024, driven by an 89.4% increase in the acute care franchise and a 60.4% increase for ZYNRELEF®.
• Also on May 6, 2025, Heron announced a settlement with Mylan Pharmaceuticals, allowing for generic entry for CINVANTI® and APONVIE® on June 1, 2032, or earlier under certain conditions.
• The Centers for Medicare & Medicaid Services’ Non-Opioid Policy took effect on April 1, 2025, establishing separate payment for non-opioid analgesics such as ZYNRELEF®.
• During Q1, the company launched the Vial Access Needle (VAN) device for streamlined ZYNRELEF® preparation and initiated development of a ready-to-use prefilled syringe (PFS) projected for early 2027.
• In a Form 8-K filed on June 18, 2025, Heron reported a material impairment of certain assets in alignment with ongoing portfolio assessments.
• On August 8, 2025, the company filed its Form 10-Q for the quarter ended June 30, 2025, detailing second-quarter financials and management’s discussion and analysis.

Financial and Strategic Analysis

Heron’s Q1 2025 performance indicates a focus on its acute care portfolio, with net revenues of $38.9 million and an adjusted EBITDA margin of approximately 16%. The company has raised its full-year 2025 adjusted EBITDA guidance to a range of $4 million–$12 million. As of March 31, 2025, the company reported cash, cash equivalents, and short-term investments totaling $50.7 million, which supports ongoing R&D and commercial efforts.

Strategically, the settlement with Mylan establishes a timeline for generic competition, allowing Heron to plan for lifecycle management and potential label expansions. The CMS policy change on April 1, 2025, provides reimbursement support for non-opioid pain therapies, and the introduction of new delivery devices (VAN, future PFS) aims to enhance hospital workflows and encourage broader adoption of ZYNRELEF®.

Market Position and Industry Context

Heron operates in two primary markets: prevention of CINV and non-opioid postoperative pain management. Its products compete with injectable antiemetics and local anesthetics, relying on differentiated dosing profiles and delivery technologies. Industry trends include increased scrutiny of opioid prescribing, rising demand for opioid-sparing strategies, and policy initiatives favoring non-opioid analgesics. Heron’s Biochronomer™ platform supports extended-release formulations, positioning the company within a sector focused on drug delivery innovation.

tl;dr

Heron reported Q1 2025 net revenue of $38.9 million and adjusted EBITDA of $6.2 million on May 6, 2025, with acute care sales rising 89.4% and ZYNRELEF® increasing by 60.4%. A June 1, 2032 settlement establishes a timeline for generic entry of CINVANTI® and APONVIE®. CMS’s April 1, 2025 Non-Opioid Policy supports non-opioid pain therapies. New device launches and a planned 2027 prefilled syringe aim to streamline ZYNRELEF® use. Full-year adjusted EBITDA guidance is set at $4 million–$12 million, backed by $50.7 million in cash as of March 31, 2025.